Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals supports innovative research and education focused on cystic fibrosis, pain, IgA nephropathy, and related diseases through investigator-initiated and competitive grant programs.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (CF, pain, IgA nephropathy) | Next cycle opens 2026 (VIA, RIA, Circle of Care)
Funding Amounts: No formal cap for most grants; VIA and Independent RIA: up to $750,000 over 2–3 years; Mentored RIA: up to $125,000 over 2 years; multi-year requests possible.
Summary: Funding for investigator-initiated research, education, and community programs in cystic fibrosis and other Vertex research areas.
Key Information: Most programs accept applications year-round; some competitive awards have annual cycles.
Description
Vertex Pharmaceuticals provides a broad range of funding opportunities for independent research, medical education, patient advocacy, and community initiatives, with a particular focus on cystic fibrosis (CF), pain, IgA nephropathy (IgAN), beta thalassemia, and sickle cell disease. Their programs support investigator-sponsored studies (ISS), educational grants, organizational sponsorships, and several competitive awards targeting early-career and established researchers in CF. Funding is designed to advance scientific knowledge, improve patient care, and address unmet needs in the community. Vertex emphasizes support for innovative research and programs that align with their therapeutic priorities.
